Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2011/263725 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552390677495808 |
|---|---|
| author | B. Uz O. Bektas E. Eliacik H. Goker Y. Erbilgin M. Sayitoglu N. Sayinalp S. Aksu Y. Buyukasik O. Ozcebe I. C. Haznedaroglu |
| author_facet | B. Uz O. Bektas E. Eliacik H. Goker Y. Erbilgin M. Sayitoglu N. Sayinalp S. Aksu Y. Buyukasik O. Ozcebe I. C. Haznedaroglu |
| author_sort | B. Uz |
| collection | DOAJ |
| description | The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era. |
| format | Article |
| id | doaj-art-cb788c174b374173920a040694e2bb51 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-cb788c174b374173920a040694e2bb512025-02-03T05:58:48ZengWileyCase Reports in Hematology2090-65602090-65792011-01-01201110.1155/2011/263725263725Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase MutationB. Uz0O. Bektas1E. Eliacik2H. Goker3Y. Erbilgin4M. Sayitoglu5N. Sayinalp6S. Aksu7Y. Buyukasik8O. Ozcebe9I. C. Haznedaroglu10Department of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Genetics, Institute of Experimental Medicine, Istanbul University, Istanbul, TurkeyDepartment of Genetics, Institute of Experimental Medicine, Istanbul University, Istanbul, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyDepartment of Hematology, Hacettepe University Medical School, 06100 Ankara, TurkeyThe current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era.http://dx.doi.org/10.1155/2011/263725 |
| spellingShingle | B. Uz O. Bektas E. Eliacik H. Goker Y. Erbilgin M. Sayitoglu N. Sayinalp S. Aksu Y. Buyukasik O. Ozcebe I. C. Haznedaroglu Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation Case Reports in Hematology |
| title | Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation |
| title_full | Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation |
| title_fullStr | Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation |
| title_full_unstemmed | Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation |
| title_short | Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation |
| title_sort | allografting for bosutinib imatinib nilotinib dasatinib and interferon resistant chronic myeloid leukemia without abl kinase mutation |
| url | http://dx.doi.org/10.1155/2011/263725 |
| work_keys_str_mv | AT buz allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT obektas allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT eeliacik allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT hgoker allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT yerbilgin allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT msayitoglu allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT nsayinalp allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT saksu allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT ybuyukasik allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT oozcebe allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation AT ichaznedaroglu allograftingforbosutinibimatinibnilotinibdasatinibandinterferonresistantchronicmyeloidleukemiawithoutablkinasemutation |